tracken
Arbutus Biopharma Corporation Aktie News
Neutral
Seeking Alpha
●
2 Tage alt
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q1 2024 Earnings Conference Call May 2, 2024 8:45 AM ET Company Participants Lisa Caperelli - Vice President, Investor Relations Mike McElhaugh - Interim President and Chief Executive Officer and Director Mike Sofia - Chief Medical Officer Karen Sims - Chief Medical Officer David Hastings - Chief Financial Officer Conference Call Participants Dennis ...
Neutral
GlobeNewsWire
●
2 Tage alt
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024
Neutral
GlobeNewsWire
●
2 Tage alt
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company's co-founder and Chief Sc...
Neutral
GlobeNewsWire
●
16 Tage alt
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 20...
Neutral
GlobeNewsWire
●
30 Tage alt
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of...
Negativ
Reuters
●
etwa ein Monat alt
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upco...
Neutral
Seeking Alpha
●
2 Monate alt
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
